Isomorphic Labs secures £458.6m in a funding round led by Thrive Capital to advance its artificial intelligence drug design engine.
The financing round was led by Thrive Capital with backing from GV and Alphabet.
Isomorphic Labs is an artificial intelligence driven drug design and development company based in London. It applies frontier machine learning models to accelerate therapeutic discovery and advance clinical pipelines.
Isomorphic Labs has secured £458.6m in its first external funding round, led by Thrive Capital. The financing also drew participation from GV, alongside follow-on backing from existing investor Alphabet. The fresh capital will be deployed to drive research and development for the company's next-generation artificial intelligence drug design engine, scale internal therapeutic programmes, and expand its team of specialists.
Founded in 2021 following breakthroughs such as AlphaFold, the London-based company combines computational biology with machine learning to model molecular interactions. Its portfolio spans partnered initiatives with pharmaceutical majors including Eli Lilly and Novartis, alongside proprietary projects focused on oncology and immunology.
From the founder
"We’re excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach."
Sir Demis Hassabis
Founder and CEO at Isomorphic Labs
Investor perspective
"At Thrive, we aim to invest in category-defining companies with singular conviction, and that has led us to Isomorphic Labs."
Joshua Kushner
Founder and CEO of Thrive Capital, Thrive Capital
Use of funds
- 01Fund research and development
- 02Grow the team
Investors
Categories
About the company
Isomorphic Labs
Isomorphic Labs develops artificial intelligence systems to design new therapeutics and accelerate drug discovery.